What is it?

Condyloma acuminata, commonly known as genital warts, represents a sexually transmitted infection caused by specific strains of human papillomavirus (HPV), predominantly types 6 and 11. These manifestations appear as benign epithelial growths (non-cancerous skin growths) in the anogenital region, including external genitalia, perineum, and perianal areas. The lesions typically present as flesh-colored, papillomatous (cauliflower-like) growths that can vary significantly in size and morphology, ranging from small, flat lesions to larger, pedunculated (stalk-like) masses.

Who is affected?

Condyloma acuminata demonstrates specific demographic patterns reflecting its sexually transmitted nature:

Age demographics: Peak incidence occurs in individuals aged 20-24 years, with prevalence highest among sexually active adults aged 17-33 years
Gender distribution: Clinical disease appears more commonly in males (75% of patients), though infection prevalence may be higher in females
Geographic prevalence: Considered the most common sexually transmitted infection in the United States
Current statistics: Affects 1.3% of US men and 3.1% of US women aged 18-59 years (2013-2016 data)
Risk populations: Individuals with multiple sexual partners, early age of sexual debut, immunocompromised states, and those with concurrent sexually transmitted infections

What causes it?

The etiology involves specific HPV viral infection with well-defined transmission patterns:

Causative agents: Human papillomavirus types 6 and 11 (responsible for approximately 90% of cases)
Transmission mechanism: Direct skin-to-skin contact during sexual activity, including genital-to-genital, oral-genital, and anal contact
Viral characteristics: Double-stranded DNA virus with tropism for squamous epithelium
Infection process: Viral invasion through microabrasions in genital skin and mucosa, targeting basal keratinocytes
Risk factors: Multiple sexual partners, immunosuppression, concurrent STIs, smoking, and lack of HPV vaccination

What are the clinical features?

Condyloma acuminata presents with characteristic lesional patterns that vary by anatomical location:

Signs (objective, observable findings):

Papillomatous growths (cauliflower-like lesions with irregular, warty surfaces)
Variable morphology: Flat, papular, or pedunculated (stalk-like) lesions
Color variations: Flesh-colored, pink, or hyperpigmented depending on skin type and location
Size range: From pinpoint lesions to large, confluent masses
Distribution patterns:
- Females: Vaginal introitus, labia, cervix, perianal region
- Males: Penile shaft (circumcised), subpreputial space (uncircumcised), perianal region
- Both sexes: Urethra, anal canal, perineum

Symptoms (subjective, patient-reported experiences):

Generally asymptomatic (majority of patients report no symptoms)
Pruritus (itching, particularly with larger or irritated lesions)
Local discomfort or pain (especially with friction or secondary infection)
Bleeding (with trauma or during intercourse)
Malodor (associated with secondary bacterial infection or poor hygiene)
Psychological distress (anxiety, embarrassment, impact on sexual relationships)

Disease progression:

Most lesions (approximately 90% of HPV exposures) remain subclinical and resolve spontaneously through host immune responses. Visible lesions may grow, remain stable, or regress without treatment. Recurrence is common following treatment.

How is it diagnosed?

Diagnosis relies primarily on clinical recognition with confirmatory testing when indicated:

Clinical assessment: Visual examination revealing characteristic papillomatous morphology in typical distributions
Acetic acid application: 3-5% acetic acid causes acetowhitening of HPV-infected tissues (not specific for condyloma)
Histopathological examination: Biopsy showing koilocytotic changes (HPV cytopathic effect) when diagnosis uncertain
HPV testing: Not routinely recommended for external genital warts but may be indicated for cervical screening
Differential considerations: Distinction from molluscum contagiosum, seborrheic keratoses, normal anatomical variants, and squamous cell carcinoma

What treatment options are available?

Management approaches include patient-applied and provider-administered therapies:

Patient-applied topical therapies:
- Podophyllotoxin 0.5% solution or gel (applied twice daily for 3 consecutive days per week, for up to 4 weeks)
- Imiquimod 5% cream (applied 3 times weekly for up to 16 weeks)
- Sinecatechins 15% ointment (green tea extract applied 3 times daily for up to 16 weeks)
Provider-administered treatments:
- Cryotherapy with liquid nitrogen (most commonly used office-based treatment)
- Trichloroacetic acid (TCA) 80-90% solution
- Electrosurgery or electrocautery
- Surgical excision (highest clearance rates approaching 100%)
- Carbon dioxide laser therapy
Treatment considerations:
- No single therapy demonstrates clear superiority
- Treatment selection based on lesion characteristics, location, patient preference, and cost
- Shared decision-making between patient and provider recommended

Key points for patients

Condyloma acuminata is caused by low-risk HPV types that do not typically progress to cancer
Treatment aims to remove visible lesions but does not eliminate underlying HPV infection
Recurrence rates are significant regardless of treatment modality chosen
Sexual partners do not require treatment unless they develop visible lesions
HPV vaccination is highly effective in preventing future infections and is recommended for eligible individuals
Condom use reduces but does not eliminate transmission risk due to potential infection of non-covered areas
Most HPV infections resolve spontaneously through natural immune responses over 1-2 years